Editas Medicine posts Q2 net loss of $53.2 mln

Editas Medicine

12/08/2025 21:15

Overview

Editas Q2 net loss at $53.2 mln, missing analyst expectations

Collaboration and R&D revenues rise significantly due to milestone payments

Operating expenses decrease following reni-cel program discontinuation

Outlook

Company plans to file IND by mid-2026

Company expects cash runway into Q2 2027

Result Drivers

COLLABORATION REVENUE - Increase in collaboration and R&D revenues driven by milestone payments from Bristol Myers Squibb partnership

PRECLINICAL DATA - New proof-of-concept data presented for gene upregulation strategy and in vivo delivery platform

EXPENSE REDUCTION - Decrease in R&D expenses due to discontinuation of reni-cel program

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration and other research and development revenue
$3.60 mln
Q2 EPS
-$0.63
Q2 Net Income
Miss
-$53.24 mln
-$33.40 mln (9 Analysts)
Q2 Basic EPS
-$0.63
Q2 Operating Expenses
$55.12 mln
Q2 Operating Income
-$51.54 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Editas Medicine Inc is $3.50, about 37.1% above its August 11 closing price of $2.20

Press Release: ID:nGNXbDXn8m

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)